AHR Stock Forecast & Price Target

American Healthcare REIT is well positioned to compound earnings because its core Integrated Senior Health Campuses and SHOP businesses are producing strong organic growth, with ISHC delivering mid-teens growth and SHOP projected to contribute nearly 19.5% SSNOI growth in '26. Its outlook is further strengthened by accretive external growth, as more than $2.4B of closed and awarded investments, including the Kensington portfolio and additional SHOP deals, should lift nFFO by an estimated 27% in '26 and 15% in '27. The balance sheet also supports expansion, with net debt-to-EBITDA at 2.5x as of 2Q26 and substantial equity-funded liquidity helping maintain flexibility while reducing refinancing risk.

American Healthcare REIT is viewed negatively because an estimated ~42% of its 2024 NOI comes from Trilogy, and roughly 24% of total NOI is tied to skilled nursing facility operating cash flows, which are unusually exposed to government reimbursement and headline risk. This concentration in higher-acuity, operationally intensive assets makes cash flow more volatile and upside more limited, even if Trilogy is considered a relatively strong operator that may better withstand industry stress. The shares also appear expensive versus fundamentals, trading at a 62.3% premium to the $31.71/sh NAV estimate and at a 4.7% implied cap rate, well below the healthcare sector average.